2010 Gene Silencing Dashboard Series 3 -

Catalog number: 1010GSL
Publication date: October 2010
Company-wide electronic copy: $3,975

Please enquire about single-user* electronic copy pricing
* single-user pricing is intended for small companies, of 40 or less employees, to access The Life Science Dashboard. Please order these copies directly with Percepta Associates.

Overview

RNA interference continues to emerge as a integral tool used to study the physiological role of gene products in vivo. RNAi-based methods allow researchers to modulate and in many cases virtually eliminate expression of a gene of interest. Systems for delivering RNAs into cells for the purpose of gene silencing include standard transfection technologies, both instrument-mediated and lipid-based, as well as plasmid and viral systems for the inducible expression of siRNAs in vivo.

Percepta’s 2010 Gene Silencing Dashboard™ dives deeply into the characteristics and dynamics of the market for gene silencing products. This 2010 Dashboard provides a snapshot of the current market landscape that can be compared with data from the 2008 and 2007 Gene Silencing Dashboard, providing an ongoing story of how the market is adapting to new products, new competitors and new sales and marketing strategies.

The Gene Silencing Dashboard™ was developed from responses to a 21-question survey completed by 281 scientists predominantly located in North America and Europe. This Dashboard reveals key market indicators for the gene silencing market as a whole as well as for the following methods representing market sub-segments:

RNAi screens using siRNA libraries (sets of 50 or more siRNAs)
Inducing siRNAs in vivo from a plasmid or other vector in cells
Digesting long dsRNA in vivo using dicer or other enzymes
Expressing siRNA in vitro for delivery into cells
Using PCS mediated siRNA expression cassettes to generate siRNAs
Instrument mediated delivery of synthetic siRNAs into cells
Lipid mediated delivery of synthetic siRNAs into cells
Instrument mediated delivery of plasmids into cells for plasmid-based gene knockdown
Lipid mediated delivery of plasmids into cells for plasmid-based gene knockdown
Viral delivery of vectors into cells for vector-based gene knockdown
Using reporter systems to track gene knockdown

Survey Methodology In July of 2010, Percepta fielded the Gene Silencing Survey to a subset of the company’s panel of life scientists. Individuals were invited by e-mail blast to click through to a webpage at bioanalytix.com where the survey was hosted. Invitations were delivered on July 21, 2010 and results collected through July 29. A total of 281 scientists completed the survey, of which 225 are actively engaged in performing gene silencing experiments and 30 plan to perform gene silencing experiments in the future. Results based on the aggregate of collected responses are revealed in this Gene Silencing Dashboard.

Respondent Demographics

Respondents from the academic, government and commercial market segments are well represented, with 20.8% of respondents employed in an industry setting. 73.0% of respondents are from North America, while 25.1% reside in Europe.
Junior (Lab Tech, Grad Students), mid level (Post-Doc, Lab Manager) and senior (Professor/PI, Group Leader) scientists are well represented in the data set, with the most cited job titles being Scientist/Senior Scientist (24.7% of respondents) and Professor / Principle Investigator (20.8%).

A wide variety of scientific areas of specialization is also evident, led by molecular biology (named by 28.9% of respondents as their primary area of expertise) and cell biology (named by 17.0% of respondents). Oncology research (9.1%) and biochemistry (7.1%) are the only other applications named by more than 7% of respondents.

Small (1-5 scientists), medium (6-20 scientists) and large (>20 scientists) laboratories are well represented: 36.1% of respondents work in labs where 1 to 5 people perform experiments; 51.2% in labs with 6 to 20 experimenters, and the remaining 12.7% in labs with greater than 20 bench scientists.

60.1% of respondents indicated that 1 to 3 people in their laboratories perform gene silencing experiments. An additional 18.5% of survey participants revealed that 4 or 5 individuals perform gene silencing experiments in their labs. Only 7.3% of respondents work in labs where greater than 10 people perform gene silencing experiments.

6 Figures and Tables
10 Executive Summary
13 Key Findings and Implications
18 Gene Silencing Dashboard
23 Gene Silencing Market Opportunity Matrix
25 Survey Methodology
27 Survey Invitation Text
28 Respondent Demographics
41 Frequency of Performance of Life Science Techniques
46 Frequency of Performance of Various Gene Silencing Methods
73 Reaction Throughput and Market Segment Growth Rates
80 Respondent’s Stated Price Per Reaction
83 Total Market Size, Market Segment Sizes and Total Market Growth Rate
85 Market Shares by Segment (Share of Mention)
119 Customer Satisfaction And Interest In Switching Suppliers
125 Product Features That Influence Purchasing Decisions
129 Primary Downstream Applications
146 Desired Changes to Gene Silencing Products
152 Survey Questionnaire

Figures and Tables

30 Figure 1: Respondent’s Place of Employment
32 Figure 2: Respondent’s Country/Region
34 Figure 3: Respondent’s Job Title
36 Figure 4A: Respondent’s Areas of Expertise/Specialization
37 Figure 4B: Respondent’s Areas of Expertise/Specialization (Molecular Biology Excluded)
40 Figure 5: Number of Employees in Respondent’s Laboratories
43 Figure 6: Percentage of Respondents Performing Various Life Science Techniques at Least a Few Times per Year
49 Figure 7: Percentage of Respondents Performing RNAi/siRNA Experiments
50 Figure 7A: Change in Percentage of Respondents Performing RNAi/siRNA Experiments
51 Figure 8: Percentage of Respondents Performing Various Gene Silencing Techniques at Least a Few Times per Year
53 Figure 9: Percentage of Respondents That Perform RNAi Screens Using siRNA Libraries
54 Figure 9A: Change in Percentage of Respondents that Perform RNAi Screens Using siRNA Libraries
55 Figure 10: Percentage of Respondents That Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
56 Figure 10A: Change in Percentage of Respondents that Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
57 Figure 11: Percentage of Respondents That Digest Long dsRNA in vivo using Dicer or other Enzymes
58 Figure 11A: Change in Percentage of Respondents that Digest Long ds RNA in vivo using Dicer or other Enzymes
59 Figure 12: Percentage of Respondents that Express siRNA in vitro for Delivery into Cells
60 Figure 12A: Change in Percentage of Respondents that Express siRNA in vitro for Delivery into Cells
61 Figure 13: Percentage of Respondents that Use PCR Mediated siRNA Expression Cassettes to Generate siRNAs
62 Figure 13A: Change in Percentage of Respondents that Use PCR Mediated siRNA Expression Cassettes to Generate siRNAs
63 Figure 14: Percentage of Respondents that Deliver Synthetic siRNAs into Cells (Instrument Mediated)
64 Figure 15: Percentage of Respondents that Deliver Synthetic siRNAs into Cells (Lipid Mediated)
65 Figure 16: Percentage of Respondents that Deliver Plasmids into Cells for Plasmid Based Gene Knockdown (Instrument Mediated)
66 Figure 17: Percentage of Respondents that Deliver Plasmids into Cells for Plasmid Based Gene Knockdown (Lipid Mediated)
67 Figure 18: Percentage of Respondents that Deliver Viral Vectors into Cells for Vector Based Gene Knockdown
68 Figure 19: Percentage of Respondents that Use a Reporter Systems to Track Gene Knockdown
69 Figure 19A: Change in Percentage of Respondents that Use a Reporter Systems to Track Gene Knockdown
90 Figure 20: Respondent’s Primary Supplier of Products for Performing RNAi Screens Using siRNA Libraries
91 Figure 20A: Changes in Respondent’s Primary Supplier of Products for Performing RNAi Screens Using siRNA Libraries
93 Figure 21: Respondent’s Primary Supplier of Products to Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
94 Figure 21A: Changes in Respondent’s Primary Supplier of Products to Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
96 Figure 22: Respondent’s Primary Supplier of Products to Digest Long ds RNA in vivo using Dicer or Other Enzymes
97 Figure 22A: Changes in Respondent’s Primary Supplier of Products to Digest Long dsRNA in vivo using Dicer or Other Enzymes
99 Figure 23: Respondent’s Primary Supplier of Products to Express siRNA in vitro for Delivery into Cells
100 Figure 23A: Changes in Respondent’s Primary Supplier of Products to Express siRNA in vitro for Delivery into Cells
102 Figure 24: Respondent’s Primary Supplier of PCR Mediated siRNA Expression Cassettes to Generate siRNAs
103 Figure 24A: Changes in Respondent’s Primary Supplier of PCR Mediated siRNA Expression Cassettes to Generate siRNAs
105 Figure 25: Respondent’s Primary Supplier of Products to Deliver Synthetic siRNAs into Cells (Instrument Mediated)
107 Figure 26: Respondent’s Primary Supplier of Products to Deliver Synthetic siRNAs into Cells (Lipid Mediated)
109 Figure 27: Respondent’s Primary Supplier of Products to Deliver Plasmids into Cells for Plasmid Based Gene Knockdown (Instrument Mediated)
111 Figure 28: Respondent’s Primary Supplier of Products to Deliver Plasmids into Cells for Plasmid Based Gene Knockdown (Lipid Mediated)
113 Figure 29: Respondent’s Primary Supplier of Products for Viral Delivery of Vectors into Cells for Vector Based Gene Knockdown
115 Figure 30: Respondent’s Primary Supplier of Reporter Systems to Track Gene Knockdown
116 Figure 30A: Changes in Respondent’s Primary Supplier of Reporter Systems to Track Gene Knockdown
124 Figure 31: Percentage of Respondents That Have Switched Suppliers in the Last Six Months
127 Figure 32: Most Important Features of Products for Gene Silencing Experiments
132 Figure 33: Respondent’s Primary Downstream Application for RNAi Screens Using siRNA Libraries
133 Figure 34: Respondent’s Primary Downstream Application for Products to Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
134 Figure 35: Respondent’s Primary Downstream Application for Products to Digest Long dsRNA in vivo using Dicer or Other Enzymes
135 Figure 36: Respondent’s Primary Downstream Application for Products to Express siRNA in vitro for Delivery into Cells
136 Figure 37: Respondent’s Primary Downstream Application for PCR Mediated siRNA Expression Cassettes to Generate siRNAs
137 Figure 38: Respondent’s Primary Downstream Application for Products to Deliver Synthetic siRNAs into Cells (Instrument Mediated)
138 Figure 39: Respondent’s Primary Downstream Application for Products to Deliver Synthetic siRNAs into Cells (Lipid Mediated)
139 Figure 40: Respondent’s Primary Downstream Application for Products to Deliver Plasmids into Cells for Gene Knockdown (Instrument Mediated)
140 Figure 41: Respondent’s Primary Downstream Application for Products to Deliver Plasmids into Cells for Gene Knockdown (Lipid Mediated)
141 Figure 42: Respondent’s Primary Downstream Application for Products to Deliver Viral Vectors into Cells for Vector Based Gene Knockdown
142 Figure 43: Respondent’s Primary Downstream Application for Reporter Systems to Track Gene Knockdown
38 Table 1: Respondent’s Areas of Expertise/Specialization Values for Figures 4A and 4B
44 Table 2: Frequency of Performance of Various Life Science Techniques
45 Table 3: Frequency of Co-Performance of Various Life Science Techniques
52 Table 4: Frequency of Performance of Gene Silencing Methods
71 Table 5: Frequency of Co-Performance of Life Science Techniques with Gene Silencing Methods
72 Table 6: Frequency of Co-Performance of Gene Silencing Methods with Life Science Techniques
75 Table 7: Median and Average Monthly Throughput for Gene Silencing Products
76 Table 8: Percentage of Respondents Performing Various Numbers of Gene Silencing Reactions Per Month
77 Table 9: Comparison to 2008 Dashboard of the Percentage of Respondents Performing Various Numbers of Gene Silencing Reactions Per Month
79 Table 10: Projected Growth in the Performance of Various Gene Silencing Techniques
82 Table 11: Median and Average Price Per Prep for Gene Silencing Products
118 Table 12: Market Share Leaders for Gene Silencing Products
121 Table 13: Percentage of Respondents Satisfied with Various Gene Silencing Products and Reasons for Dissatisfaction
122 Table 14: Percentage of Respondents Satisfied with Various Gene Silencing Products: Comparison to 2008 Dashboard
128 Table 15: Most Important Features of Products for Gene Silencing Experiments – Comparison to 2008 Gene Silencing Dashboard
143 Table 16: Respondent’s Primary Application for Various Gene Silencing Methods
145 Table 17: Respondent’s Primary Application for Various Gene Silencing Methods – Comparison to 2008 Gene Silencing Dashboard

[Download not found]

Available upon request

Purchase Now

Reports